| Identification | Back Directory | [Name]
Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chloro- | [CAS]
711085-63-1 | [Synonyms]
PNU 282987 free base
(R)-4-Chloro-N-(quinuclidin-3-yl)benzamide
4-chloro-N-[(3R)-quinuclidin-3-yl]benzamide
Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chloro-
N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide | [Molecular Formula]
C14H17ClN2O | [MDL Number]
MFCD08703110 | [MOL File]
711085-63-1.mol | [Molecular Weight]
264.75 |
| Chemical Properties | Back Directory | [Boiling point ]
431.5±30.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [solubility ]
DMF: 10 mg/ml; DMSO: 30 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 5 mg/ml | [form ]
A crystalline solid | [pka]
13.86±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
PNU-282987 is a highly selective α7 nicotinic acetylcholine receptor agonist (1,2). PNU-282,987 has been utilized to generate retinal neurons in the absence of retinal injury or exogenous growth factors in rat (1). PNU-282,987 has the potential to reverse vision loss due to neurodegenerative disease or aging. | [Definition]
ChEBI: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide is a carbonyl compound and an organohalogen compound. | [in vivo]
PNU-282987 (free base) (Compound C7) (i.v.; 1, 3 mg/kg) leads to a reversal of the gating deficit[1].
PNU-282987 (30 μM) evokes currents in rat hippocampal neurons in a concentration-dependent and MLA blockable manner[1]. | Animal Model: | Rats[1] | | Dosage: | 1, 3 mg/kg | | Administration: | i.v. | | Result: | Significantly reversed amphetamine-induced gating deficit. |
| [IC 50]
5-HT3 Receptor | [storage]
Store at RT |
|
|